Latest News

Date Title Topic
20 Dec 2013 NSCLC Maintenance Therapy: Bevacizumab or Pemetrexed? Lung and other thoracic tumours
19 Dec 2013 Systems medicine paves the way for improved treatment for AML patients Personalised medicine - Translational research - Haematologic malignancies
18 Dec 2013 Misunderstanding of Palliative Care Palliative and supportive care
17 Dec 2013 ESMO Signalling Pathways Symposium 2014: targeting the PI3K/AKT/mTOR pathway
17 Dec 2013 A Study of Anastrozole in Breast Cancer Chemoprevention Breast cancer - Cancer prevention
16 Dec 2013 Obinutuzumab/Chlorambucil in the First-Line Treatment of Older CLL Patients Cancer in Special Situations - Haematologic malignancies - Anticancer agents & Biologic therapy
13 Dec 2013 ESMO Press Release: Defending Medical Oncology to Assure Quality Care for Cancer Patients
12 Dec 2013 Phase III Study of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukaemia Haematologic malignancies - Anticancer agents & Biologic therapy
11 Dec 2013 CALR Mutations in Myeloproliferative Neoplasms Translational research - Haematologic malignancies
Pre-IMPAKT 2014 Training Course
09 Dec 2013 Learning From the FDA Breakthrough Therapies Pathway Bioethics, legal and economic issues - Anticancer agents & Biologic therapy
Alan Howard, ESMO’s Chief Executive Officer since 2009, has announced he is stepping down, to become effective as of January 2014.
05 Dec 2013 APO-SYS: How Modulation of Apoptosis Can be Used in the Treatment of Cancer and AIDS Translational research
ESMO German National Representative Elections